An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Roche

Status: Terminated

Conditions: Rheumatoid Arthritis

Study type: Observational

Funder types: Industry

Identifiers

NCT01277328

ML25332

Details and patient eligibility

About

This observational, prospective, open-label, multi-center study will evaluate the effectiveness in disease reduction and the safety of RoActemra/Actemra (tocilizumab) in patients with rheumatoid arthritis. Data will be collected for 11 months.

Enrollment: 95 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients >/=18 years of age
• Patients with rheumatoid arthritis eligible for RoActemra

Exclusion criteria

• Hypersensitivity to RoActemra
• Active, severe infections

Trial design

95 participants in 1 patient group

Cohort

Description:

Cohort